More data for Inspra in heart failure

Pfizer Inc. (NYSE:PFE) reported additional data for Inspra eplerenone in the Phase IIIb EMPHASIS-HF trial for chronic heart failure, which met the composite primary endpoint in a May interim analysis. On the endpoint, 18.3% of patients receiving Inspra plus standard of care (SOC) had an incidence of cardiovascular death or heart failure hospitalization compared to 25.9% of patients treated with placebo plus SOC (p<0.0001). On secondary endpoints, Inspra plus SOC significantly reduced all-cause mortality, CV mortality, all-cause hospitalization and heart failure hospitalization vs. placebo plus SOC. The double-blind, international trial enrolled 2,737 patients with New York Heart Association (NYHA) class II chronic systolic heart failure. ...